Lannett could see decreased digoxin sales, says Craig-Hallum Last week an article in the Journal of American College of Cardiology, or JACC, highlighted concerns regarding increased mortality for Digoxin users. Craig-Hallum said Digoxin is one of Lannett's top drugs and believes the study combined with the push-back on last year's price increase could lead to a decrease in Digoxin sales. Shares are Buy rated but the analyst is growing more cautions near-term.
Senate Health, Education, Labor & Pensions Committee to hold a hearing The Subcommittee on Primary Health and Aging holds a hearing entitled, "Why Are Some Generic Drugs Skyrocketing In Price?" with President & CEO Vigodman of Teva Pharmaceutical and President & CEO Bedrosian of Lannett Company on November 20 at 1 pm. Webcast Link